Literature DB >> 4082105

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration.

L Bara, E Billaud, G Gramond, A Kher, M Samama.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082105     DOI: 10.1016/0049-3848(85)90244-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  26 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Low molecular weight heparin.

Authors:  P A Routledge; R R West
Journal:  BMJ       Date:  1992-10-17

Review 4.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  Low molecular weight heparin in immunological recurrent abortion--the incredible cure.

Authors:  Gautam N Allahbadia; Swati G Allahbadia
Journal:  J Assist Reprod Genet       Date:  2003-02       Impact factor: 3.412

Review 6.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 7.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 8.  Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.

Authors:  Marco P Donadini; Walter Ageno; James D Douketis
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

Review 9.  Enoxaparin. A review of its clinical potential in the management of coronary artery disease.

Authors:  S Noble; C M Spencer
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan.

Authors:  J C Stiekema; J M Van Griensven; T G Van Dinther; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.